Regardless of progress made in most cancers immunotherapy, some sufferers don’t reply to those remedies or they cease responding after a time frame. Eikon Therapeutics’ lead drug candidate might deal with these limitations. This program is in scientific testing in two frequent varieties of most cancers and Eikon has raised $381 million in IPO money to assist this drug and others in its pipeline.
Late Wednesday, Eikon priced its providing of 21.2 million shares at $18 apiece, up from the 17.6 million shares the corporate initially deliberate to supply within the vary of $16 to $18 every. These shares started buying and selling on the Nasdaq Thursday underneath the inventory image “EIKN.” Eikon’s inventory market debut builds on rising biotech IPO momentum. Aktis Oncology had the primary biotech IPO of the yr in January. Veradermics started buying and selling as a public firm Wednesday. All three corporations have been in a position to upsize their offers.
Millbrae, California-based Eikon discovers and develops medicine utilizing proprietary expertise that permits visualization and evaluation of proteins. However the firm’s most superior applications got here from enterprise offers. Lead program EIK1001 was licensed from Seven and Eight Biopharmaceuticals in 2023. This small molecule is a twin agonist of toll-like receptors 7 and eight (TLR 7/8), an method supposed to activate each innate and adaptive immune responses to most cancers.
Using TLR agonists to deal with most cancers has been restricted by systemic toxicity, Eikon stated in its IPO submitting. One approach to keep away from that drawback is by administering the remedy instantly into tumors. However Eikon stated this method been ineffective, maybe because of the failure to activate the innate immune system in secondary lymphoid tissues, comparable to immune cells within the lymph nodes and spleen. Eikon stated it has recognized a dose and schedule to permit for systemic administration of EIK1001, enabling the remedy to succeed in these tissues.
A Section 2 research is ongoing, testing EIK1001 together with the Merck checkpoint inhibitor Keytruda and chemotherapy as a therapy for non-small cell lung most cancers (NSCLC). Preliminary information present responses and discount in tumor sizes. Eikon plans to submit information from this trial for presentation at a medical assembly within the second half of this yr.
A separate Section 2/3 registrational trial is underway testing EIK1001 together with Keytruda in superior melanoma. Eikon expects the primary interim evaluation from this research within the second half of 2026, after which it plans to pick the optimum dose. Eikon can also be continuing with a scientific trial designed to judge EIK1001 in stage 4 NSCLC. This world Section 2/3 registrational research will take a look at the research drug together with Keytruda and chemotherapy. Eikon expects to dose the primary affected person within the second half of this yr. Eikon says its lead drug candidate might discover broader use.
“We additionally imagine that the design of EIK1001 to activate innate and adaptive immune anti-tumor responses creates the potential to discover extra indications, together with each extremely immunogenic tumors, which have been proven to be vulnerable to immunotherapy, and reasonably and low immunogenic tumors, the place present immune therapies have demonstrated little to no exercise,” the corporate stated within the IPO submitting.
The Eikon pipeline consists of two PARP inhibitors, EIK1003 and EIK1004. These medicine, each licensed from Impression Therapeutics, are selective to PARP1, sparing PARP2. This selectivity might have a security benefit over presently accessible PARP inhibitors that include a danger of blood issues that will come from inhibiting PARP2. Within the submitting, Eikon says it believes the selectivity of its PARP inhibitors might allow combos with chemotherapy in earlier traces of therapy in addition to sustained therapeutic dosing throughout upkeep therapy. A Section 1 dose-escalation research is underway for EIK1003 as a monotherapy for ovarian, breast, and prostate cancers.
In the meantime, a world Section 1/2 research is underway testing EIK1004 in ovarian, breast, prostate, and pancreatic cancers. Eikon believes this drug’s capability to penetrate the central nervous system might allow therapy of sufferers with superior strong tumors, with or with out mind metastases. The corporate believes this drug additionally has potential functions treating major mind cancers.
Eikon’s most superior internally found program is EIK1005, an inhibitor of WRN helicase, an enzyme that performs a task in DNA harm restore. The corporate believes this drug might be used to deal with excessive microsatellite instability tumors, as a monotherapy or together with immunotherapy. A Section 1/2 research is underway enrolling sufferers with superior strong tumors.
Eikon was based in 2019 and emerged from stealth in 2021, revealing $148 million in funding and former Merck govt Roger Perlmutter as its CEO. Previous to the IPO, Eikon had raised greater than $1.1 billion; its most up-to-date financing was a $350.7 million Collection D spherical practically a yr in the past.
As of the top of 2025, Eikon reported its money place was $336 million. In response to the submitting, Eikon plans to spend about $100 million to proceed scientific improvement of lead program EIK1001 in superior melanoma and NSCLC. One other $60 million is earmarked for finishing a Section 1/2 take a look at of EIK1003. Capital can also be budgeted for early scientific improvement of EIK1004 and EIK1005.
Picture: Getty Pictures
